A child died in Russia after use of Zolgensma drug for the treatment of spinal muscular atrophy, reports Reuters Referring to the Swiss company – the manufacturer of the drug Novartis.
According to Novartis, the boy died of acute liver failure that occurred after five to six weeks of infusion of the drug. In Russia, Zolgensma was registered at the end of 2021.
In addition, a child from Kazakhstan suffering from SMA died with similar symptoms.
Previously at the Ministry of Health declarationHe said that the Russian drug for SMA will go on sale in 2026.
SMA drugs are the most expensive and complex drugs in the world – gene-modifying drugs like Zolgensma, which are administered once, after which SMA no longer threatens a person’s health. The most effective treatment for SMA is early detection and administration of the drug before the age of two. Zolgensma costs $2 million per dose.